Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 20;30(18):2110-2153.
doi: 10.1089/ars.2016.6930. Epub 2017 May 15.

From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

Carlo Gabriele Tocchetti  1 , Christian Cadeddu  2 , Daniela Di Lisi  3 , Saveria Femminò  4 , Rosalinda Madonna  5   6 , Donato Mele  7 , Ines Monte  8 , Giuseppina Novo  3 , Claudia Penna  4 , Alessia Pepe  9 , Paolo Spallarossa  10 , Gilda Varricchi  1   11 , Concetta Zito  12 , Pasquale Pagliaro  4 , Giuseppe Mercuro  2
Affiliations
Review

From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

Carlo Gabriele Tocchetti et al. Antioxid Redox Signal. .

Abstract

Significance: Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX is associated with irreversible cardiac cell injury, and it is typically caused by anthracyclines and traditional chemotherapeutics. Type II CTX is generally caused by novel biologics and more targeted drugs, and it is associated with reversible myocardial dysfunction. Therefore, patients undergoing anti-cancer treatments should be closely monitored, and patients at risk of CTX should be identified before beginning treatment to reduce CTX-related morbidity. Future Directions: Genetic profiling of clinical risk factors and an integrated approach using molecular, imaging, and clinical data may allow the recognition of patients who are at a high risk of developing chemotherapy-related CTX, and it may suggest methodologies to limit damage in a wider range of patients. The involvement of redox mechanisms in cancer biology and anticancer treatments is a very active field of research. Further investigations will be necessary to uncover the hallmarks of cancer from a redox perspective and to develop more efficacious antineoplastic therapies that also spare the cardiovascular system.

Keywords: ErbB2 inhibitors; cancer immunotherapy; chemotherapy; oxidative/nitrosative stress; tyrosine kinase inhibitors; vascular endothelial growth factor.

PubMed Disclaimer

Figures

<b>FIG. 1.</b>
FIG. 1.
Concentric representation of cardiotoxic effects of anthracyclines. ROS, reactive oxygen species.
<b>FIG. 2.</b>
FIG. 2.
Simplified algorithm showing the factors related to anthracycline therapy or patient characteristics that may determine cardiac damage.
<b>FIG. 3.</b>
FIG. 3.
ErbB receptor homodimerization or heterodimerization is induced by stressors, including anthracycline therapy, with consequent complex intracellular pathway activation. Cascade effects can be avoided by treatment with monoclonal antibodies and TKIs. See the text for further explanation. EGFR, epidermal growth factor receptor; ErbB2 (or HER2), human epidermal growth factor receptor 2; ERK, extracellular signal-regulated kinase; TKIs, tyrosine kinase inhibitors.
<b>FIG. 4.</b>
FIG. 4.
VEGFR activation triggers a complex intracellular pathway. Cascade effects can be avoided by treatment with anti-angiogenic drugs acting at various levels of the cascade. See the text for further explanation. MAPK, mitogen-activated protein kinase; NO, nitric oxide; NOS, nitric oxide synthase; VEGFR, vascular endothelial growth factor receptor.
<b>FIG. 5.</b>
FIG. 5.
Schematic illustration of how TKI antagonists induce cardiac damage; these drugs can increase arterial pressure and ventricular-vascular coupling, leading to heart failure. PDGFR, platelet-derived growth factor receptor; VEGF, vascular endothelial growth factor.
<b>FIG. 6.</b>
FIG. 6.
Role of CTLA-4 and its interaction with ipilimumab in tumor immunity. (A) Dying tumor cells release tumor neo-antigens that are taken up by APCs, which then present B7 co-stimulatory molecules to T cells. T cells recognize tumor neo-antigens on APCs and are activated. Activated T cells upregulate inhibitory checkpoints, such as CTLA-4 and PD-1, which block T cell activation and attack of tumor cells. (B) Ipilimumab blocks CTLA-4, resulting in T cell activation and destruction of tumor cells. See the text for further explanation and acronyms. APCs, antigen-presenting cells; CTLA-4, cytotoxic T lymphocyte-associated protein 4; PD-1, programmed cell death 1; TCR, T cell receptor.
<b>FIG. 7.</b>
FIG. 7.
Main cardiotoxic mechanism and effects induced by antimetabolite drugs. See the text for further explanation. 5-FU, 5-fluorouracil; HF, heart failure; RNS, reactive nitrogen species; ROS, reactive oxygen species.
<b>FIG. 8.</b>
FIG. 8.
Physiological function of the redox system. See the text for further explanation. GPx, glutathione peroxidase; H2O2, hydrogen peroxide; NOSs, nitric oxide synthases; ONOO−, peroxynitrite; SNO, S-nitrosylation; SOD, superoxide dismutase.
<b>FIG. 9.</b>
FIG. 9.
In the case of excessive production of superoxide anion (O2•−) and other ROS/RNS, lipid and protein oxidation/nitration may occur, with consequent alteration of the activity of many enzymes, leading to cell death. The dashed arrow represents the onset of a vicious cycle affecting redox enzymes. See the text for further explanation. NOX, NAD(P)H oxidase.
<b>FIG. 10.</b>
FIG. 10.
Antioxidant properties of NO. When production of NO is adequate, the formation of nitrosylating agents may prevail, including N2O3, which can mediate a direct thiol nitrosylation of proteins, which, in turn, may affect the regulatory function in many physiological processes. See the text for further explanation.
<b>FIG. 11.</b>
FIG. 11.
Drugs and cardioprotective strategies against antineoplastic-induced cardiotoxicity. The main mechanism(s) of protection are reported. See the text for further explanation. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NRG1, neuregulin 1; Top2, topoisomerase 2.
<b>FIG. 12.</b>
FIG. 12.
Simplified algorithm showing how cancer therapy alone or together with demographic and conventional risk factors may determine cardiac damage; both factors can increase myocardial and arterial stiffness, thus impairing ventricular-vascular coupling and, finally, leading to HF, with either decreased ejection fraction (EF) or preserved EF (HFPEF). CV, cardiovascular.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abd El-Aziz MA, Othman AI, Amer M, and El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 21: 469–473, 2001 - PubMed
    1. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, and Valent P. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86: 533–539, 2011 - PubMed
    1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, and Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14–25, 2010 - PMC - PubMed
    1. Alhawiti N, Burbury KL, Kwa FA, O'Malley CJ, Shuttleworth P, Alzard M, Hamadi A, Grigg AP, and Jackson DE. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res 145: 54–64, 2016 - PubMed
    1. Alter P, Herzum M, Soufi M, Schaefer JR, and Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 4: 1–5, 2006 - PubMed

Publication types

MeSH terms

Substances